Eylea
Novartis’ Beovu approved in Europe after outclassing Eylea in wet age-related macular degeneration
February 18, 2020Manufacturing and Production, Sales and Marketing Beovu, Eylea, Novartis, Regeneron, macular degeneration, pharma
The European Commission (EC) has chosen to approve Novartis’ Beovu (brolucizumab) injection, it has emerged, as a treatment for wet …
Bayer’s Eylea shows strong vision benefits across two regimens in post-marketing study
February 5, 2020Research and Development Bayer, Eylea, pharma
Bayer has pulled back the curtain on new Phase 4 data for Eylea (aflibercept), revealing strong findings in the treatment …
FDA approves Novartis’ Beovu injection for wet age-related macular degeneration
October 8, 2019Manufacturing and Production, Sales and Marketing Beovu, Eylea, FDA, Novartis, Regeneron, pharma
Novartis has secured FDA approval for its Beovu (brolucizumab) injection in the treatment of wet age-related macular degeneration (AMD), it …
FDA expands indication for Eylea to cover all stages of diabetic retinopathy
May 14, 2019Manufacturing and Production Bayer, Eylea, FDA, Regeneron, approval, pharma
The FDA has expanded the indication for Regeneron’s Eylea (aflibercept) to include all stages of diabetic retinopathy. Regeneron chief scientific …
Courts back NHS in fight against Novartis and Bayer
September 24, 2018Sales and Marketing Bayer, Eylea, NHS, Novartis, avastin, ludentis
The NHS has won a court case against multinational pharmaceutical firms Novartis and Bayer, after the companies sought to block …
Regeneron’s Eylea wins FDA approval for wet age-related macular degeneration
August 20, 2018Sales and Marketing Bayer, Eylea, FDA, Regeneron, US, pharma
Regeneron is celebrating the approval in the US of its vascular endothelial growth factor (VEGF) inhibitor Eylea (aflibercept) for the …
Regeneron’s Eylea smashes Phase 3 trial goal in diabetic retinopathy
March 20, 2018Manufacturing and Production, Research and Development Eylea, Regeneron, diabetes, pharma
Regeneron has confirmed that its vascular endothelial growth factor (VEGF) inhibitor injection Eylea (aflibercept) met its primary endpoint in a …
Top Ten most popular articles on Pharmafile.com this week
February 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Alzheimer's, AstraZeneca, Eylea, FDA, Microsoft, Regeneron, Shire, Tremfya, eurordis, multiple myeloma, rare disease
It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …
Reports increasing of worrying side-effects with Regeneron’s Eylea
February 22, 2018Medical Communications, Research and Development, Sales and Marketing Eylea, FDA, Regeneron, pharma
Reports are emerging which detail some pretty alarming side-effects in patients receiving Regeneron’s blockbuster eye drug Eylea: once injected into …
Regeneron forced to drop Eylea combo, advantage Novartis
November 27, 2017Manufacturing and Production, Research and Development Eylea, Novartis, Regeneron, biotech, drugs, pharma, pharmaceutical
Novartis released Phase 3 data on its leading candidate for wet age-related macular degeneration (AMD) drug and it caused a …
NICE recommends Bayer’s Eylea for myopic chorodial neovascularisation
September 22, 2017Medical Communications, Sales and Marketing Bayer, Eylea, NICE, pharma, pharmaceutical
Bayer has revealed that UK drug regulator NICE has given its final recommendation on blockbuster eye drug Eylea (aflibercept solution …
Novartis receives positive news in eye drug P3 studies
June 20, 2017Manufacturing and Production, Research and Development Eylea, Novartis, Regeneron
Novartis has achieved positive feedback from its two Phase 3 studies into its eye drug RTH258 (brolucizumab), which found it …
Regeneron’s Eylea fails combination study endpoint
October 3, 2016Research and Development, Sales and Marketing Eylea, Regeneron
Regeneron has announced that its eye drug Eylea (aflibercept) failed its primary endpoint in a mid-stage trial investigating its effectiveness …
NICE approves Bayer’s Eylea for NHS use
September 28, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Eylea, NICE
Bayer has announced that its Eylea (aflibercept) drug has received a final recommendation from NICE for the treatment of visual …
NICE recommends Eylea as first-line treatment for sight threatening condition
August 24, 2016Research and Development, Sales and Marketing Bayer, Eylea, NHS, NICE, first-line treatment
Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Eylea (aflibercept) as a cost-effective …
Latest content
FibroFind appoints Lee Borthwick as CEO
